Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Dow
McKesson
Mallinckrodt
Baxter

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Lanreotide acetate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for lanreotide acetate and what is the scope of freedom to operate?

Lanreotide acetate is the generic ingredient in one branded drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lanreotide acetate has seventy-one patent family members in seventeen countries.

There are three drug master file entries for lanreotide acetate. One supplier is listed for this compound.

Summary for lanreotide acetate
International Patents:71
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 3
Suppliers / Packagers: 1
Bulk Api Vendors: 34
Clinical Trials: 3
Patent Applications: 5,563
DailyMed Link:lanreotide acetate at DailyMed
Recent Clinical Trials for lanreotide acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
IpsenPhase 1/Phase 2
IpsenPhase 3
IpsenPhase 4

See all lanreotide acetate clinical trials

Pharmacology for lanreotide acetate
Synonyms for lanreotide acetate
108736-35-2
118992-92-0
123369-01-7
127984-74-1
127984-74-1 (acetate salt)
3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2 inverted exclamation marku7)-disulfide acetate
3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-->7)-disulfide acetate
3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide
3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (27)-disulfide
3-(2-Naphtyl)-D-Ala-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Thr-NH2
33928-EP2272827A1
33928-EP2275420A1
33928-EP2295055A2
33928-EP2295416A2
33928-EP2295426A1
33928-EP2295427A1
33928-EP2298748A2
33928-EP2298764A1
33928-EP2298765A1
33928-EP2305642A2
33928-EP2311453A1
33928-EP2311808A1
33928-EP2311829A1
AC1L2FZT
AC1OCEWT
AKOS030573447
AN-33681
Angiopeptin acetate
Autogel
BDBM82470
BIM 23014
Bim-23014
C54H69N11O10S2
CHEBI:135901
CHEMBL1201185
CTK8G7572
DB06791
DC 13-116
GTPL2031
Ipstyl
L-Threoninamide, 3-(1-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
L000343
Lanreotida
Lanreotida [INN-Spanish]
Lanreotide
Lanreotide [INN:BAN]
Lanreotide Autogel
Lanreotide; Angiopeptin; 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide; 127984-74-1
Lanreotidum
Lanreotidum [INN-Latin]
LS-153748
LS-172394
Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2
NCGC00181321-01
PUDHBTGHUJUUFI-UHFFFAOYSA-N
SCHEMBL14802383
SCHEMBL34091
Somatulin
Somatulin-Autogel
Somatuline

US Patents and Regulatory Information for lanreotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-002 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-002 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Mallinckrodt
Express Scripts
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.